uniQure N.V. – Filings and Transcripts

NASDAQ: QURE
Share price (11/4/26): $23.03
Market cap (11/4/26): $1.598 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 09/30/26 Q3

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

Prospectuses and Registrations Filter

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

JPMorgan Chase & Co.

Rtw Investments, LP

Susquehanna Securities, LLC

Aberdeen Group Plc

News Filter

~ FDA Granted Priority Review of BLA for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease; PDUFA Target Action Date of May 1, 2027 ~

Announces FDA Acceptance and Priority Review of the Biologics License Application for Ifezuntirgene Inilparvovec for the Treatment of Huntington’s Disease

Announces Additional Data From Ongoing Phase I/II Studies of Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression

Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease

Announces Second Quarter 2026 Financial Results and Provides Company Update

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Additional info about upcoming vote

Definitive proxy

Other Filter

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Scanned paper annual report submission

Confidential treatment order